In conclusion, although the current study design cannot distinguish whether significantly improved insulin sensitivity in response to long-term treatment with linagliptin is a direct or secondary effect, the data suggest that it may be the result of significantly reduced liver fat content in diet-induced hepatic steatosis and insulin resistance animal model. This evidence concerns the gene INS and Insulin resistance.